DelveInsight’s ‘Catheter-Related Bloodstream Infection (CRBSI) Market’ report delivers an in-depth understanding of the CRBSI historical and forecasted epidemiology, market trends in the geographies listed below.
The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates) and Russia
Catheter-Related Bloodstream Infection Overview
Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease. Antibiotic lock therapy is considered adjunctive therapy in the treatment of CRBSI when catheter removal is not a favorable option. The current treatment options are used as off-label therapies and only a few non-antibiotic lock solutions are approved in Europe.
CRBSI Epidemiology Key Findings
This section provides glimpses of the catheter-related bloodstream infection epidemiology in the global market.
As per DelveInsight’s analysis, the total incident population of catheter-related bloodstream infections in the global market was found to be 4,114,882 in 2017. The estimates show a higher incidence of catheter-related bloodstream infection in India with 1,722,280 cases in 2017.
CRBSI Marketed Drugs
1. Neutrolin by CorMedix
2. Taurosept by Geistlich Pharma
CRBSI Off-label Drugs
CRBSI Emerging Drugs
1. Mino-Lok: Citius Pharmaceuticals
CRBSI Market Outlook
The catheter-related bloodstream infection market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted catheter-related bloodstream infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
According to DelveInsight, the catheter-related bloodstream infection global market is expected to change in the study period 2017–2030.
This section includes a glimpse of the catheter-related bloodstream infection global market. The market size of CRBSI in the Global market was USD 1,237.38 million in 2017.
Download our full report: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
Table of contents
1 Key Insight
2 Executive Summary of Catheter-Related Bloodstream Infection (CRBSI)
3 Catheter-Related Bloodstream Infection (CRBSI) Market Overview at a Glance
4 Disease Background and Overview: Catheter-Related Bloodstream Infection (CRBSI)
5 Case Reports
6 Catheter-Related Bloodstream Infection (CRBSI) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Catheter-Related Bloodstream Infection (CRBSI) Treatment and Medical Practices
11 Unmet needs
12 Catheter-Related Bloodstream Infection (CRBSI) Marketed Drugs
13 Catheter-Related Bloodstream Infection (CRBSI) Emerging Drugs
14 Catheter-Related Bloodstream Infection (CRBSI) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Catheter-Related Bloodstream Infection (CRBSI) Market Drivers
19 Catheter-Related Bloodstream Infection (CRBSI) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States